Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has historically done well, developing treatments for infectious diseases. Still, Barclays believes the stock a ...

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a leading immunotherapy stock by hedge funds, reporting strong fiscal Q4 and full year 2025 results, driven by the growth of Biktarvy, Descovy, and the launch of Yeztugo, the first twice-yearly HIV prevention therapy in the country [1] Financial Performance - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, primarily due to higher sales of HIV and Liver Disease products, although this was partially offset by lower sales of Veklury® [2] Analyst Ratings - Following the earnings release, several analysts updated their ratings for Gilead. Needham raised the price target to $170 from $140 while maintaining a Buy rating, and Scotiabank increased its target to $177 from $140, keeping an Outperform rating [3] - BofA also raised its price target to $162 from $154, maintaining a Buy rating, and expressed confidence in the company's growth for 2026 based on strong fiscal Q4 performance [4] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [5]

Core Insights - Gilead Sciences, Inc. (GILD) reported strong fourth-quarter and full-year 2025 results, with HIV product sales increasing by 6%, driven by a 7% growth in Biktarvy and a 47% surge in its prevention portfolio [1][2][10] Group 1: HIV Product Performance - Biktarvy holds over 52% market share in the HIV treatment market and is the most prescribed therapy for both treatment-naïve and switch patients [2] - Descovy's sales increased by 31% year over year to $2.8 billion, accounting for more than 45% of the U.S. market share in pre-exposure prophylaxis (PrEP) [3] - The FDA approved injectable lenacapavir (Yeztugo), which offers a twice-yearly dosing schedule, enhancing adherence compared to daily oral regimens [4] Group 2: Financial Projections and Growth Drivers - Despite a $900 million headwind from the Medicare Part D redesign, HIV sales grew 10% when excluding this impact, surpassing management's annual target of 5% growth [2][10] - Gilead expects total HIV sales to grow approximately 6% year over year in 2026, with potential growth of 8% when excluding pricing pressures and channel mix shifts [6] - Early uptake of Yeztugo generated $150 million in 2025, with projected revenues of approximately $800 million in 2026 [5] Group 3: Research and Development Initiatives - Positive phase III results from ARTISTRY-1 and ARTISTRY-2 studies for the investigational BIC/LEN regimen increase the likelihood of regulatory approval, potentially launching by year-end [7] - Gilead is collaborating with Merck to advance its HIV pipeline, with data from studies on islatrovir plus lenacapavir expected in 2026 [8] - Plans to initiate a phase III study evaluating lenacapavir plus broadly neutralizing antibodies are set for the second half of the year [9] Group 4: Competitive Landscape - Gilead faces competition from major players like GSK and Merck in the HIV treatment market, with GSK's growth driven by long-acting injectable medicines [11] - Merck markets doravirine and is evaluating a once-daily oral regimen for treatment-naïve adults with HIV-1 infection [12] Group 5: Stock Performance and Valuation - GILD shares surged 45.9% over the past year, outperforming the industry's growth of 19.6% [15] - The current price/earnings ratio for GILD is 17.46x forward earnings, higher than its historical mean but lower than the large-cap pharma industry average of 18.51x [16]

Group 1 - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a strong investment opportunity by hedge funds, with BofA raising its price target to $162 from $154 while maintaining a Buy rating [1] - The company reported strong fiscal Q4 and full year 2025 results, highlighting the successful launch of Yeztugo, the first twice-yearly HIV prevention therapy, and continued growth in Biktarvy and Descovy [2] - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, driven by higher sales of HIV and Liver Disease products, despite a decline in Veklury® sales [3] Group 2 - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [4]

Core Viewpoint - Gilead Sciences is experiencing strong financial performance and growth potential, particularly in its HIV and liver disease segments, supported by a robust pipeline of new products and an optimistic outlook from analysts [1][2][3][4][6]. Financial Performance - Gilead's Q4 2025 earnings report showed total product sales of $7.9 billion, marking a 5% increase year-over-year [2][6]. - For the full year 2025, total sales reached $28.9 billion, reflecting a 1% increase from 2024 [2][6]. - HIV sales specifically grew by 6% year-over-year, driven by the success of the drug Biktarvy and a 47% increase in the HIV prevention portfolio [2][6]. Product Developments - The new HIV prevention injectable, Yeztugo, has surpassed coverage goals and is gaining market share [3][6]. - Gilead's pipeline includes up to 10 ongoing and potential new launches through 2027, with four commercial launches planned for 2026 [3][6]. - The liver business reported a 6% growth, attributed to the adoption of Livdelzi for primary biliary cholangitis [4][6]. - Trodelvy, an oncology product, also demonstrated positive momentum with a 6% growth in 2025, supported by favorable Phase results [4][6]. Analyst Ratings - BMO Capital has maintained an "Outperform" rating for Gilead, raising the price target from $150 to $160, indicating confidence in the company's future performance [1][6].

Core Viewpoint - Gilead Sciences, Inc. reported strong fourth-quarter results for 2025, with adjusted earnings per share (EPS) of $1.86, exceeding estimates, while total revenues of $7.9 billion also surpassed expectations, driven by growth in HIV and Liver Disease drugs [1][4][6]. Financial Performance - Adjusted EPS for Q4 2025 was $1.86, beating the Zacks Consensus Estimate of $1.83, but down from $1.90 a year ago due to higher acquired IPR&D expenses [1][6]. - Total revenues reached $7.9 billion, a 5% increase year over year, surpassing the Zacks Consensus Estimate of $7.6 billion [1][4]. - Product sales increased by 5% year over year to $7.9 billion, with HIV product sales growing 6% to $5.8 billion [4][5]. Product Sales Breakdown - Biktarvy sales rose 5% year over year to $4 billion, capturing over 52% of the U.S. HIV treatment market [5][6]. - Descovy sales surged 33% year over year to $819 million, driven by increased demand for HIV prevention [6][7]. - Liver Disease portfolio sales increased 17% to $844 million, exceeding estimates, primarily due to demand for Livdelzi [8]. - Veklury sales fell 37% to $212 million, attributed to lower COVID-19 hospitalization rates [8]. Cost and Expenses - Adjusted product gross margin was 86.8%, slightly up from 86.7% year over year [11]. - Research and development expenses remained flat at $1.6 billion, while SG&A expenses decreased to $1.7 billion from $1.9 billion [11][12]. 2025 and 2026 Guidance - For 2025, revenues rose 2% year over year to $29.4 billion, exceeding estimates, with adjusted EPS increasing to $8.15 from $4.62 in 2024 [13]. - Gilead expects 2026 product sales between $29.6 billion and $30 billion, with adjusted EPS projected in the range of $8.45-$8.85 [14][15]. Pipeline and Regulatory Updates - Positive phase III results for the investigational regimen of bictegravir and lenacapavir were reported, with a potential launch targeted for the second half of the year [16][23]. - Gilead has discontinued several studies based on recommendations from independent committees, including the phase III STAR-221 study [18][19]. Market Position and Competitive Landscape - Gilead's HIV business exceeded management's growth target, driven by strong performances from Biktarvy and Descovy, despite competitive pressures [21][22]. - The company anticipates continued competitive pressures in cell therapies and expects to face headwinds from U.S. government drug pricing agreements [24][27].

Core Viewpoint - Gilead Sciences (GILD.US) shares rose over 5% to a record high of $155.54 following the release of its financial results, indicating strong performance and growth potential in the market [1] Financial Performance - For the full year 2025, Gilead reported total revenue of $29.443 billion, representing a year-over-year increase of 2.4% [1] - The net profit attributable to the company was $8.51 billion, showing a significant year-over-year increase of approximately 16.73 times [1] - Non-GAAP diluted earnings per share reached $8.15, reflecting a substantial year-over-year growth of 77% [1] Product Development and Market Position - Gilead's Chairman and CEO, Daniel O'Day, highlighted that the previous year was fruitful for the company, marked by the successful launch of Yeztugo, the world's first semi-annual HIV prevention therapy [1] - The continued growth of Biktarvy and Descovy has established a solid foundation for the company's future growth [1]

Core Viewpoint - Gilead Sciences Inc. reported strong fourth-quarter earnings but provided weak guidance for fiscal 2026, leading to a decline in share price [1][2]. Financial Performance - Gilead reported quarterly earnings of $1.86 per share, exceeding the consensus estimate of $1.81 [1]. - Quarterly revenue reached $7.93 billion, surpassing the Street estimate of $7.69 billion [1]. Future Guidance - For fiscal 2026, Gilead expects adjusted EPS in the range of $8.45 to $8.85, compared to the analyst estimate of $8.74 [2]. - Revenue guidance for fiscal 2026 is projected between $29.6 billion and $30 billion, below the analyst estimate of $30.22 billion [2]. Analyst Ratings and Price Targets - Needham analyst Joseph Stringer maintained a Buy rating and raised the price target from $140 to $170 [4]. - Scotiabank analyst Louis Chen maintained a Sector Outperform rating and increased the price target from $140 to $177 [4]. - Cantor Fitzgerald analyst Carter Gould maintained an Overweight rating and raised the price target from $135 to $155 [4]. Market Reaction - Following the earnings announcement and guidance, Gilead shares fell 1.8% to $144.55 in pre-market trading [2].

Core Viewpoint - Gilead expects its HIV portfolio sales to grow by 6% in 2026, driven by the recently launched PrEP drug Yeztugo, despite facing some headwinds from regulatory agreements and market conditions [1][2][6] Sales Performance - Gilead's HIV drugs generated $20.8 billion in sales for the full year 2025, marking a 6% increase from 2024, primarily due to the strong performance of Biktarvy, which saw sales rise by 7% to $14.3 billion [1][4] - The company anticipates total product sales between $29.6 billion and $30 billion in 2026, factoring in a decline in demand for Veklury, a Covid-19 antiviral [5] Yeztugo's Impact - Yeztugo, a biannual PrEP option, achieved $150 million in sales in 2025 after its FDA approval in June, with expectations to reach $800 million in 2026, representing a 433% year-over-year growth [3][6] - Analysts from Citi believe that the sales target for Yeztugo is achievable, indicating strong market potential [3] Future Projections - GlobalData forecasts that Yeztugo will continue to grow, potentially reaching $5.34 billion in annual sales by 2031, supported by ongoing demand for HIV prevention [4] - Gilead's CEO emphasized the company's secure business outlook, with no major loss of exclusivities until 2036, suggesting a stable growth trajectory [6]

Group 1 - Gilead Sciences' 2026 financial forecast is at the lower end of analyst expectations, leading to a nearly 2% drop in stock price [1] - The company reported Q4 2025 sales and profits slightly above Wall Street expectations, with quarterly sales of its HIV prevention drug Yeztugo reaching $96 million, surpassing the forecast of $88 million [1] - Gilead expects Yeztugo sales to be $800 million in 2026, lower than the analyst forecast of $907 million, with a noted discrepancy from investor expectations of $1 billion [1] Group 2 - Yeztugo has shown nearly 100% effectiveness in clinical trials for HIV prevention, offering hope to curb the annual 1.3 million new infections globally [2] - The annual U.S. list price for Yeztugo is approximately $28,000, causing some hesitation among potential users, although 90% of U.S. payers have agreed to cover the drug's cost [2] - Gilead projects adjusted earnings per share for 2026 to be between $8.45 and $8.85, while analysts expect an average of $8.75, which is 10 cents higher than Gilead's midpoint forecast [2]